# Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

> **NCT02815059** · PHASE1 · WITHDRAWN · sponsor: **University of Utah**

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Dasatinib
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02815059
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-09-28
- **Primary completion:** 2018-01-09
- **Final completion:** 2018-01-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Termination of Investigator Initiated Studies using Ibrutinib
- **Last updated:** 2018-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02815059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02815059, "Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02815059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*